PCIF1-mediated m6Am modification activates USP5/BRD4 axis to promote glycolysis-driven immunosuppression in multiple myeloma.
A metabolic-epigenetic pathway controlling myeloma cell immunity emerges as a target for combination drug therapy.
This Int Immunopharmacol study delineates a PCIF1/m6Am/BRD4 regulatory axis that promotes immunosuppression in multiple myeloma through aerobic glycolysis. The pathway represents a potential therapeutic target for combining metabolic and epigenetic inhibitors to restore anti-tumor immunity in myeloma.
What the study was
- Study design
- Preclinical mechanistic study
- Population
- Multiple myeloma cell lines
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- International immunopharmacology
Why it surfaced
Int Immunopharmacol; PCIF1/m6Am/BRD4 immunosuppression axis in MM; novel epigenetic-metabolic target; preclinical in vitro study.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.